arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

XOMA Royalty Corp

XOMA
$40.32 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

XOMA Royalty Corp shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $487.1M
Dividend Yield
Revenue Growth 83.1%
Op. Margin 21.8%
ROIC 6.3%
FCF / Share $0.24
Trailing P/E 26.4x
Price / Book 5.7x
FCF Yield 0.6%
Debt / Equity 1.15
info Valuation on last close. End-of-day price, Jul 13, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$52.15M
↑ +83.1%
Net Income Profit after all expenses
$31.71M
↑ +329.4%
Operating Margin Operating profit as % of sales
21.8%
↑ +115.6% 78th
FCF / Share Free cash flow per share
$0.24
↑ +120.2%
Long-Term Debt Long-term obligations
$96.45M
↓ -9.8%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
74
Returns
95
Financial Health
39
Cash Quality
25

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters